Signs and symptoms of overdose with Remodulin (treprostinil sodium) during clinical trials are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of Remodulin (treprostinil sodium) .

In controlled clinical trials, seven patients received some level of overdose and in open-label follow-on treatment seven additional patients received an overdose; these occurrences resulted from accidental bolus administration of Remodulin (treprostinil sodium) , errors in pump programmed rate of administration, and prescription of an incorrect dose. In only two cases did excess delivery of Remodulin (treprostinil sodium) produce an event of substantial hemodynamic concern (hypotension, near-syncope).

One pediatric patient was accidentally administered 7.5 mg of Remodulin (treprostinil sodium) via a central venous catheter. Symptoms included flushing, headache, nausea, vomiting, hypotension and seizure-like activity with loss of consciousness lasting several minutes. The patient subsequently recovered.

None

Last reviewed on RxList: 4/4/2011
This monograph has been modified to include the generic and brand name in many instances.